Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of VDJ001 in healthy subjects
NCT06021574Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VDJ-001 in rheumatoid arthritis (RA) (4 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Adverse events up to 57 days, Pharmacokinetics-AUC0-t up to 57 days and 6 more. Started Jun 2019; status: completed.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06021574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021574.